OBJECTIVES: To analyze the risk of first ischemic stroke in patients using nervous system drugs. METHODS: Population-based, matched case-control study using hospital registry including all patients with an incident stroke discharge diagnosis between 2009-2015. Cases were matched 1:10 with controls obtained from the Information System for Research in Primary Care (SIDIAP) database. Drug exposure information was obtained from pharmacy invoice data. Crude and adjusted odds ratios (OR, ORadj) and their 95% confidence interval (95%CI) were calculated using multivariate models of conditional logistic regression for antiepileptics, antipsychotics, anxiolytics, hypnotics, antidepressants, psychostimulants, and anti-dementia drugs. RESULTS: 12,616 cases were matched to 125,264 controls by gender, age and health area. Women were 43% of the cases. Mean age was 72.6 (IQR 65-82) years and more cases were classified as high cardiovascular risk (2,511, 19.9%) than controls (12,467, 10.0%). Mortality in the following year after index date was higher for cases (2,633, 20.9%) than for controls (8,168, 6.5%). More cases than controls had a previous diagnostic of ischemic heart disease, 13.8% (1,745) vs 7.7% (9,656). Anxiolitics were the most used drugs [6,536 (51.8%) for cases and 55,698 (44.5%) for controls] and anti-dementia drugs the least [861 (6.8%) cases and 8,046 (6.4%) controls]. All therapeutics drugs showed risk for stroke. After adjustment, we found risk of ischemic stroke for antiepileptics exposure [ORadj 1.41, (95%CI) 1.35-1.48], antypsychotics (
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PCV3 IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINE
Sha'aban A 1 , Zainal H 1 , Muhamad AS 2 , Hammad MA 1 , Ibrahim B 1 1 Universiti Sains Malaysia, Penang, Malaysia, 2 Hospital Pulau Pinang, Penang, Malaysia OBJECTIVES: Low Dose Aspirin (LDA) is the cornerstone of secondary prevention in Coronary Artery Disease (CAD). Despite its established efficacy, it has a prime limitation arising from its gastric toxicity. The reason why some patients develop clinically significant toxicities while others develop no or minor toxicities is yet to be demystified. This study aims at identifying biomarkers for Low Dose Aspirin (LDA)-induced gastric toxicity and efficacy in CAD patients, which may enable personalization of LDA therapy. METHODS: CAD patients attending the cardiac clinic of Hospital Pulau Pinang that satisfy the study inclusion criteria were recruited after informed consent. Blood samples of recruited patients were obtained at baseline(Pre) and after one month(Post) of initiating LDA therapy. For each patient, Complete blood count was ordered and the Pre-and Post-LDA serum were analyzed using Proton nuclear magnetic resonance (1H NMR) spectroscopy to identify the biomarkers that may distinguish between those with and without gastric toxicity. RESULTS: Thirty-eight percent (38%) of the 74 patients that meet up with the inclusion criteria had a history of gastric toxicity. Chi-square test indicated a significant difference between the means of those with and without gastric toxicity (P-value: 0.001). Multinomial logistic regression indicated Platelet count between 150-180x103/mL as a significant predictor of gastric toxicity to LDA (rs: 0.021, p-value: 0.004). Preliminary results of the 1H NMR pharmacometabolomic analysis show some metabolites that are potential biomarkers for LDA-induced gastric toxicity in CAD patients. CONCLUSIONS: This study clearly demonstrates the gastric toxicity of LDA. Multivariate statistical analysis and validation to ascertain these discriminating metabolites that may be linked to the gastric toxicity is ongoing.
PCV4 NON CARDIOVASCULAR COMORBITY AND PROGNOSIS OF CONGESTIVE HEART FAILURE
Aizpuru F 1 , Garmendia I 2 , Millan E 3 , Trujillo TG 2 , Librero J 4 1 Osakidetza/Basque Health Service, Vitoria-Gasteiz, VI, Spain, 2 Bioef, Vitoria-Gasteiz, Spain, 3 Osakidetza/Basque Health Service, Vitoria-Gasteiz, Spain, 4 Navarrabiomed, Pamplona, Spain OBJECTIVES: Non-cardiovascular (non-CV) comorbidities of Congestive Heart Disease (CHD) are associated with a worse self-perceived perception of health than cardiovascular (CV) morbidities. This study assessed the association between the record of admissions for any cause in the 12 months before a first admission by CHF (index admission) and mortality within the following 30 and 365 days. METHODS: Patients with a first admission for CHF in any of the hospitals of Osakidetza/Basque Health Service between 2011 and 2015 were followed up for one year after the index admission. Clinical and demographic data at discharge was extracted from the electronic health record, as well as the history of hospitalizations during the previous 12 months. Logistic regression methods were used to identify the association between last hospitalization before the index admission (CV, non-CV, no admission) and mortality at 30 and 365 days, adjusting for patient demographics (age, sex, socioeconomic status-SES), and clinical (Charlson index) baseline (time of discharge) characteristics. RESULTS: The study included 15,101 patients with a first admission for CHF (mean age 80y, SD 10; 51% female; Charlson index 2, SD 1). After covariate adjustment, and compared with those without admissions in the previous year, those admitted for a non-CV cause had a greater risk of death at 30 days (OR: 1.4; CI 95% 1.2-1.7; p<0.001) and at 365 days (OR: 1.4; CI 95% 1.3-1.5; p<0.001). If the previous admission was for a CV cause, the risk of death was greater at 365 days (OR: 1.2; CI 95% 1.0-1.3; p¼0.024) but not within the first 30 days following the index admission. CONCLUSIONS: This study provides real-world evidence on the role of non-CV comorbidities on the prognosis of CHF. Attention should be paid to these comorbidities before progression to more advanced stages of the disease. (EJPC 2017; 24:1843) to explore the implications of LDL-C lowering achieved by lomitapide using baseline (treated with statins, ezetimibe, apheresis (67%)) and lomitapide-treated LDL-C levels from a cohort of HoFH patients (AdvTher 2017; 34:1200) . RESULTS: Modelling predicted this cohort of HoFH patients, mean age 37.6 years with mean baseline LDL-C level 11.02mmol/L, who had LDL-C reduced by lomitapide by 68% (mean last visit value), to gain median 11.6 life years (LY) (mean 9.4) and delay median age of death to 53. If nadir LDL-C lowering of 76% is used, median LY gained is 12.5 (mean 10).~80% of patients are modelled to have had a MACE by age 37.6; therefore, lomitapide has marginal impact on this. Treating the same cohort of HoFH patients with lomitapide at age 18 is modelled to further extend life expectancy, by a median 19.4 years (mean 14.5) to age 61, and delay time to first MACE by median 11.5 years (mean 8.3) to age 40. This increases to median gain of 20.2 LY and delay of 12.6 years for first MACE if the 76% nadir LDL-C reduction is used. CONCLUSIONS: LDL-C reductions achieved with lomitapide in the real world are modelled to increase life-expectancy by a median of >11 years, even when started at an average age 37.6, or by >19 years when prescribed from age 18. This suggests that lomitapide has the potential to show significant survival benefits via lowering of LDL-C when used as an adjunct to SOC in HoFH patients.
PCV6 SACUBITRIL/VALSARTAN IN HEART FAILURE: PROJECTED HEALTH OUTCOMES IN PORTUGAL
Afonso-Silva M, Laires PA Novartis Farma, Porto Salvo, Portugal OBJECTIVES: Sacubitril/valsartan showed superior efficacy in the treatment of heart failure with reduced ejection fraction (HFrEF). This study aimed to estimate the projected health outcomes, namely hospitalizations, deaths, life years (LY) and quality-adjusted life years (QALY), following different levels of HFrEF patient access to sacubitril/valsartan in Portugal. METHODS: A Markov model was used to describe HFrEF progression and associated lifetime outcomes. It was calibrated with the PARADIGM-HF data (e.g. treatment effects and EQ-5D to derive utilities) and adapted to the Portuguese reality. A nationwide epidemiological study (EPICA) and other published literature provided key model's inputs, such as country-specific age, gender, and prevalence of HF in Portugal. This model provides relevant outputs, as hospitalizations and deaths that could be avoided, as well as LY and QALY that could be gained with different sacubitril/valsartan patient access levels. A 5-year time horizon was considered. RESULTS: In a scenario where half of the eligible HFrEF population is treated with sacubitril/valsartan, it is estimated that 6,876 hospitalizations will potentially be avoided in the next 5 years (1,742 hospitalizations due to HF, 2,548 due to other cardiovascular events and 2,585 non-cardiovascular). If sacubitril/valsartan is used in only 20% of the eligible population, the estimated number of hospitalizations potentially avoided reduces to 2,750. It is also estimated that 965 deaths can potentially be prevented if sacubitril/valsartan is used in 50% of the eligible population, decreasing to 386 if used in 20% of patients. The benefits of sacubitril/valsartan also translate into 2,466LY and 2,869QALY gained if sacubitril/ valsartan is adopted in 50% of the eligible population, versus 986LY and 1,148QALY gained if adopted in 20% of the eligible population. CONCLUSIONS: We projected a favorable impact of sacubitril/valsartan in HFrEF Portuguese patients' morbidity and mortality. Improving access to this innovative treatment may generate considerable health outcomes in the Portuguese society.
PCV7 COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE US
Tsang Y 1 , Drake W 2 , Pruett J 3 1 Actelion Pharmaceuticals Ltd., South San Francisco, CA, USA, 2 Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA, 3 Actelion Pharmaceuticals, Inc., South San Francisco, CA, USA OBJECTIVES: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance that can lead to right heart failure and premature death. Two oral prostacyclin pathway drugs, oral treprostinil and selexipag, are used to treat PAH. To date there are no head-to-head studies comparing effectiveness of these two drugs. The study objective is to compare the effect of oral treprostinil to selexipag on hospitalization among PAH patients. METHODS: A retrospective administrative claims study was conducted using the Optum Clinformatics Data Mart database to identify patients 18 years with pulmonary hypertension who were prescribed oral treprostinil or selexipag between January 1, 2015 to September 30, 2017 (index date). Patients were required to have continuous enrollment in the baseline period ( 6 months) prior to index date. Patients with an index drug at baseline or switched to another index drug at any time during the entire study period V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) S 1 eS 4 8 1 S93
